Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables - Accured (2024 - 2025)

Historic Receivables - Accured for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $3.3 million.

  • Kura Oncology's Receivables - Accured rose 7368.42% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 7368.42%. This contributed to the annual value of $3.3 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Receivables - Accured is $3.3 million, which was up 7368.42% from $3.6 million recorded in Q2 2025.
  • Kura Oncology's Receivables - Accured's 5-year high stood at $3.9 million during Q1 2025, with a 5-year trough of $1.5 million in Q1 2024.